ASU

ASU — avocado-soybean unsaponifiables — is one of the few dietary supplements that has achieved something close to pharmaceutical respectability in osteoarthritis management. In France and several other European countries, the proprietary formulation Piascledine is prescribed as a SYSADOA (symptomatic slow-acting drug for osteoarthritis) and is reimbursed by national health systems. This regulatory status reflects a body of evidence that, while modest in effect size, is more consistent than many competing supplements.

The extract is produced by saponifying avocado and soybean oils, then isolating the unsaponifiable fraction — the sterols, tocopherols, and fat-soluble compounds that resist hydrolysis. The standardized ratio is approximately one-third avocado to two-thirds soybean unsaponifiables. In chondrocyte and synovial cell cultures, ASU has been shown to stimulate collagen and aggrecan synthesis while simultaneously inhibiting the matrix metalloproteinases that degrade cartilage. This dual anabolic-catabolic mechanism is rare among natural products and gives ASU a theoretically sound foundation.

A 2019 meta-analysis in the International Journal of Rheumatic Diseases pooled available RCT data and found that ASU significantly reduced pain by visual analog scale in knee osteoarthritis, with a weighted mean difference of -17.36 mm (p<0.0001). However, the same analysis found no significant benefit for hip osteoarthritis, suggesting joint-specific effects. A 2003 systematic review in Clinical Rheumatology noted that three of four RCTs showed efficacy, though the only long-term trial was largely negative. The structural data is perhaps most interesting: a 2011 three-year RCT in Osteoarthritis & Cartilage found that ASU significantly reduced loss of joint space width in hip OA compared to placebo — a disease-modifying endpoint that few supplements can claim.

The practical limitations are significant. The strongest evidence belongs to the prescription formulation Piascledine, manufactured by Expanscience Laboratories under strict pharmaceutical standards. Generic ASU supplements may not use the same extraction process, standardization, or raw material sourcing, and their equivalence is unproven. In the United States, ASU is available as a dietary supplement but without the regulatory oversight that ensures European product quality.

Safety is generally favorable. Soy and avocado allergies are contraindications. Gastrointestinal upset is the most common adverse effect, occurring at rates similar to placebo. The lipid nature of the extract means it should be taken with a meal containing some fat for optimal absorption.

For consumers with knee osteoarthritis, particularly those in Europe with access to prescription-grade Piascledine, ASU is a reasonable evidence-based option with both symptomatic and structural support data. In markets where only generic supplements are available, consumers should be cautious about assuming equivalence to the clinically tested formulation.